Purpose Our case series aims to study the growing use of FDG PET/CT in diagnostic evaluation and follow up of IgG4-RD with emphasis on patients presenting with coronary artery involvement. Methods We conducted a search on the nuclear medicine and rheumatology service databases and identified patients with histologically proven IgG4-RD with FDG PET/CT performed at the Singapore General Hospital. The radiological, clinical, and laboratory findings of these patients were analyzed retrospectively. Results The series included ten male and two female patients. The commonest organ involved (five patients) was the pancreas. In three patients, coronary artery involvement manifested as soft tissue masses surrounding the arterial lumens. In these patients, histological diagnosis was established from alternative biopsy sites with abnormal metabolic activity on FDG PET/CT.
Introduction
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a disorder that was first described in 2003, when extrapancreatic manifestations of disease were identified in patients with autoimmune pancreatitis [1] .
The use of positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (FDG PET/CT) for IgG4-RD has slowly been increasing [2] . With FDG PET/CT, whole-body surveys could be performed in a single sitting, disease could be detected early before clinical relapse, and physicians could assess treatment response before anatomical changes are discernable [3] . IgG4-RD can often be confused with other multi-system conditions such as lymphoma because of the myriad of organs that may be involved. Where the initially detected lesions are in locations with anatomically difficult access, a further potential strong point of FDG PET/CT would be the detection of alternative sites for histological confirmation of IgG4-RD.
We report a case series of patients with IgG4-RD who underwent FDG PET/CT at Singapore General Hospital (SGH). Interestingly, although our numbers are small, we had a relatively large proportion (three out of 12) of coronary artery involvement. We are adding a small case series to the growing body of evidence of coronary involvement in IgG4-RD [4] [5] [6] [7] [8] [9] .
Materials and Methods
We conducted a retrospective analysis of all patients at SGH with histologically proven IgG4-RD who had had an FDG PET/CT at any point in their clinical course. These patients were identified by searching the database at the Department of Nuclear Medicine and PET and the Department of Rheumatology of the Singapore General Hospital. The reports and images of the scans were accessed by authors 1, 3, 4, and 5 separately, and information on metabolic and morphologic abnormalities was recorded. If patients had repeated FDG PET/CT scans done, these were also recorded and the changes of a semi-quantitative measurement (SUVmax) were noted. The standardized uptake value (SUV), an index of FDG uptake in tissue, was computed as follows: SUV = region of interest activity/(injected radioactivity/body weight). Lesional SUVmax to liver background SUVmax ratios were also calculated. Liver background SUVmax (ranging from 3.0 to 4.0) was measured within a spherical volume of interest (diameter, 50 mm) positioned in an area of normal liver tissue in the right lobe).
Approval was granted by SGH's institutional review board for this study and waiver of consent was obtained.
FDG PET/CT scans were performed using an LSObased PET/CT scanner (GE Discovery 690, Wisconsin, USA) with 64-slice CT using 3D acquisition (FOV 70 cm diameter) and time of flight system with iterative reconstruction, according to guidelines set out by the Society of Nuclear Medicine and European Association of Nuclear Medicine [10, 11] . Scans were performed 60 to 110 min post injection of FDG.
Information recorded included demographic data, date of diagnosis, organs involved, and treatment information. Conventional radiologic imaging (ultrasonography [US], contrast-enhanced CT, and magnetic resonance imaging [MRI] ) and laboratory results of patients were also Correlation between SUVmax and laboratory results were studied using Spearman's rank correlation coefficient (rho).
Results

Demographics
A total of 12 patients (ten male and two female) were identified over a nine-year period. All patients were diagnosed to have IgG4-RD by the 2011 comprehensive diagnostic criteria (Table 1 ) [12] . The median age at diagnosis was 58 years old (range 49 to 81). Eleven patients were of Chinese ethnicity, whilst one was Malay ( Table 2 ). The time between initial scan (CT/MRI/FDG PET/CT) to subsequent FDG PET/CT ranged from 1 week to 4 years, with the median time frame being 4 months.
Scan Features
The commonest organs involved radiologically at time of presentation were the pancreas (five patients (42%)) followed by the coronary arteries, and the salivary/ lacrimal glands (three patients (25%) respectively). Coronary artery involvement was part of a multi-system disease in the three patients included, but none had presenting symptoms related to the coronary arteries, for example acute coronary syndromes or dissections (Table 3) . Coronary artery involvement manifested as hypermetabolic soft tissue masses surrounding the arterial lumens (Figs. 1, 2 and 3) , an appearance that has very rarely been described in one of the key alternative diagnoses of lymphoma [13] . In all patients who had coronary artery involvement, the site of biopsy for initial diagnosis of IgG4-RD was remote from the coronary arteries (iliac vessel, kidney, and lip), but these biopsy sites were all shown to be FDG-avid on PET.
The median (range) SUVmax of lesions was 5.2 (2.7-12.8) in patients with positive FDG PET/CT. The median (range) ratio of lesional SUVmax to liver background SUVmax (SUVR) was 1.59 (0.90 to 4.27) (Fig. 4) .
Laboratory Features
At initial diagnosis, all patients had IgG4 levels between 22 and >340 mg/dL, with median level of 191 mg/dL. There was no statistically significant correlation between IgG4 levels, CRP, ESR, and SUVmax (Figs. 5, 6 and 7) in our series. 
Follow-up
Patients were not on prednisolone at time of initial FDG PET/ CT, but follow-up studies were done with ongoing treatment with immunosuppressants. Four patients had follow-up FDG PET/CT (Table 4) , coincidentally including the three patients with coronary artery involvement. Three showed interval reduction in metabolic activity to background levels uniformly in all organs involved from a mean SUVmax of 6.9, with the shortest time being 3 months after treatment with oral prednisolone. In one of these patients, there was resolution of the coronary arterial lesions (Figs. 8 and 9 ). The fourth patient had been scanned multiple times with FDG PET/CT. However, after his repeat FDG PET/CT showed abnormal raised metabolic activity (SUVmax 4.2) in the coronary arteries and in the lymph nodes, an increase in steroid dose was guided by the metabolic imaging results. No flare-up of disease and no increase in prednisolone dosing were noted in the two years of follow-up in the three patients with good response on FDG PET/CT.
Discussion
There have been several retrospective [14] and prospective [15] studies evaluating the use of FDG PET/CT in IgG4-RD. To date, the use of FDG PET/CT to image the disease is still gaining traction. We hope to add to the increasing body of evidence suggestive of benefit and highlight the increasing roles of FDG PET/ CT in particular to guide biopsy site for diagnosis in patients where initial imaging showed difficult sites to biopsy (such as coronary arteries) as well as to evaluate disease response and recurrence.
Our study features a small case series of involvement of the coronary arteries. This may be related to the increasing use of CT coronary angiography or CT chest for other diagnostic purposes. These patients tend to have FDG-avid soft tissue nodular lesions or thickening surrounding all three of the coronary vessels. This is different from the usual pattern of aneurysms which tend to occur in involvement of the coronary vessels by other vasculitides [16] .
The suspicion of IgG4-RD should be raised in patients with disease involvement of the coronary arteries with periarterial masses. Their clinical behavior tended to be similar to that of patients without coronary artery involvement, presenting without symptoms related to coronary artery involvement, and with radiological and In our patients, we found that biopsy proven IgG4-RD shows SUVmax up to 12.8. Because there is still considerable overlap in terms of SUVmax with the majority of lymphoproliferative disorders, differentiation is not possible on the grounds of SUVmax alone although it can be suggested by the relatively lower levels and the pattern of uptake. Potential weaknesses of this study are that it is a retrospective review of relatively small numbers of a fairly heterogeneous group of patients, and thus the strength of conclusions drawn from this may not be as robust as in other larger studies. However, given the relative rarity of the condition and in particular of coronary artery involvement, our study adds to the growing awareness and literature of the use of FDG PET/ CT for evaluation of IgG4-RD.
Conclusion
In conclusion, the evidence for using FDG PET/CT in evaluating IgG4-RD is slowly growing. FDG PET/CT is a useful tool in evaluation and follow-up of IgG4-RD particularly in selecting alternative biopsy sites in patients who present with coronary artery involvement. Hypermetabolic coronary artery masses on FDG PET/CT should raise suspicion of IgG4-RD. As the coronary artery masses may not show decrease in size after treatment, FDG PET/CT is also useful for metabolic response assessment. 
